Anlon Healthcare: Should You Buy, Hold, or Sell Right Now?
- September 8, 2026
- Posted by: Kunal Singla
- Category: Market
Anlon Healthcare share price Rs 15.48 (NSE), near its 52-week high. 52-week range Rs 8.70 to Rs 17.28. Q1 FY27 profit up sharply YoY to Rs 8.28 crore.
Quick Answer
Anlon Healthcare Ltd share price is trading around Rs 15.5, roughly 10 percent below its 52-week high of Rs 17.28 and nearly double its 52-week low of Rs 8.70. Q1 FY27 revenue grew strongly to Rs 87.62 crore, up from Rs 33.31 crore a year earlier, with net profit up to Rs 8.28 crore from Rs 3.55 crore. Full-year FY26 revenue grew 43 percent to Rs 172.22 crore with profit up 41.8 percent to Rs 29.09 crore from Rs 20.52 crore in FY25. The stock trades at a discount of 24.50 times earnings against the specialty chemicals sector average near 37.7 times.
Anlon Healthcare share price is trading close to its 52-week high of Rs 17.28, with Anlon Healthcare share price around Rs 15.5 on the NSE, nearly double its 52-week low of Rs 8.70. With very strong growth continuing in Q1 FY27, investors are asking whether this pharmaceutical intermediates manufacturer is a stock to buy at the current discount, a hold, or a sell.
This Anlon Healthcare stock analysis walks through the Q1 FY27 numbers, valuation against the specialty chemicals sector, shareholding pattern and the technical setup, using figures sourced from company disclosures and public filings.
Click Here – Get Free Investment Predictions
About Anlon Healthcare
Before deciding on Anlon Healthcare share price, it helps to understand the underlying business. Anlon Healthcare Ltd. manufactures pharmaceutical intermediates and specialty chemicals, serving domestic and export pharmaceutical customers.
As a pharmaceutical intermediates manufacturer, Anlon Healthcare has delivered very strong, consistent growth across recent periods, with the most recent quarter continuing an accelerating trend visible through FY26.
Anlon Healthcare Share Price Today: Key Levels
The table below summarises where Anlon Healthcare share price stands right now against its recent trading range and market value.
| Metric | Value |
|---|---|
| Anlon Healthcare CMP (NSE) | Rs 15.48 |
| Anlon Healthcare CMP (BSE) | Rs 15.49 |
| 52-Week High | Rs 17.28 |
| 52-Week Low | Rs 8.70 |
| Market Capitalisation | Approximately Rs 833 crore |
Anlon Healthcare share price is trading close to its 52-week high, having nearly doubled from its 52-week low, reflecting strong investor confidence in the company’s consistent growth.
Check the Univest Screener for Live Stock Data
Anlon Healthcare Financial Performance
The Anlon Healthcare share price trend is closely tied to how these numbers evolve each quarter. Anlon Healthcare reported Q1 FY27 (June 2026 quarter) revenue of Rs 87.62 crore, up sharply from Rs 33.31 crore a year earlier, with net profit growing to Rs 8.28 crore from Rs 3.55 crore, continuing a strong sequential improvement from Rs 50.9 crore revenue in the March 2026 quarter.
For the full year FY26, the company reported revenue of Rs 172.22 crore, up 43 percent year on year from Rs 120.46 crore, with net profit of Rs 29.09 crore, up 41.8 percent from Rs 20.52 crore in FY25, confirming the growth trend has been sustained across the full year and into the new fiscal year.
| Period | Revenue | Net Profit | Comment |
|---|---|---|---|
| Q1 FY27 (Jun 2026) | Rs 87.62 crore | Rs 8.28 crore | Very strong growth YoY and sequentially |
| FY26 (full year) | Rs 172.22 crore | Rs 29.09 crore | +43% revenue, +41.8% profit YoY |
Valuation Check: Is Anlon Healthcare Share Price Expensive?
Any view on Anlon Healthcare share price should start from these valuation multiples. Anlon Healthcare share price currently reflects a price to earnings ratio of about 24.50 times trailing earnings, a discount to the broader specialty chemicals sector average of roughly 37.7 times. The price to book ratio stands near 3.6 times, supported by a strong 12.38 percent return on equity.
Debt to equity of 0.19 is low. Given the very strong and consistent growth visible across recent quarters, this discount valuation could offer room for re-rating if the growth pace is sustained.
Technical Signals: What the Chart Shows
Price action here often foreshadows the next move in Anlon Healthcare share price. Anlon Healthcare share price is currently positioned roughly 10 percent below its 52-week high of Rs 17.28, nearly double its 52-week low of Rs 8.70, reflecting a very strong overall run over the past year. A stock trading this close to its high, backed by consistent strong growth, typically signals the market rewarding tangible execution.
Trading volumes remain very heavy, so investors should track Anlon Healthcare share price alongside continued order growth and margin trends in coming quarters, rather than reacting to any single day’s move at these technical levels.
Download the Univest iOS App or Univest Android App to track Anlon Healthcare’s live price and technical levels.
Shareholding Pattern
Shifts here can influence Anlon Healthcare share price more than headline news on some sessions. Anlon Healthcare is a promoter-led pharmaceutical intermediates and specialty chemicals manufacturer. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company’s latest exchange filing.
Why Investors Are Watching Anlon Healthcare
- Very strong and consistent growth: Both Q1 FY27 and full FY26 showed very strong revenue and profit growth, a consistent trend across recent periods.
- Discount valuation to sector: A 24.50x PE against a 37.7x specialty chemicals sector average offers meaningful valuation cushion given the strong growth.
- Strong stock performance over the past year: The stock has nearly doubled from its 52-week low, reflecting sustained investor confidence.
Risks and Factors to Watch
- Sustainability of the very rapid growth pace: The very strong recent growth rate would need to be sustained over further quarters to justify continued re-rating.
- Specialty chemicals sector competitive pressure: Anlon Healthcare competes against other domestic and international pharmaceutical intermediates manufacturers.
- Raw material and input cost cyclicality: As a chemicals manufacturer, the company faces exposure to raw material price cycles that can affect margins.
- Stock at a high valuing in continued growth: Trading close to its 52-week high leaves some room for disappointment if the growth pace slows.
Anlon Healthcare Share Price Target: What the Data Suggests
Until then, Anlon Healthcare share price remains best tracked through live, verified data rather than a single fixed number. Anlon Healthcare does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. What the data shows is a company delivering very strong, consistent growth, trading at a discount to the specialty chemicals sector.
Investors who want live, updated research can check the Univest Screener, and should consult a SEBI-registered investment adviser for guidance tailored to their own goals.
Anlon Healthcare: Should You Buy, Hold, or Sell Right Now?
This is the core question behind Anlon Healthcare share price right now. The Anlon Healthcare buy or sell decision depends on whether the current growth trajectory can be sustained.
The case for buying: Growth-focused investors who believe in Anlon Healthcare’s pharmaceutical intermediates business and see the discount to sector PE as attractive may find the current level, near its 52-week high, reasonable given the growth delivered.
The case for holding: Existing shareholders who already track Anlon Healthcare’s growth trajectory may prefer to stay invested and monitor continued execution.
The case for waiting: Investors wanting a larger valuation cushion before committing fresh capital may prefer to wait for a more attractive entry point.
Historically, specialty chemicals manufacturers with consistent strong growth have rewarded patient investors, so weigh this against your own risk tolerance and consult a SEBI-registered investment adviser if unsure.
Conclusion
Anlon Healthcare share price reflects a pharmaceutical intermediates manufacturer delivering very strong, consistent growth in Q1 FY27 and full FY26, trading close to its 52-week high at a discount to the specialty chemicals sector. This article is for informational purposes and not a personalised investment recommendation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Q1. Is Anlon Healthcare a good stock to buy right now?
Ans. Anlon Healthcare delivered very strong revenue and profit growth in both Q1 FY27 and full FY26. The stock trades at a discount to the specialty chemicals sector, which may appeal to growth investors who believe the momentum can continue.
Q2. What is the Anlon Healthcare share price today?
Ans. Anlon Healthcare share price is trading around Rs 15.5 on the NSE, close to its 52-week high of Rs 17.28. The stock’s 52-week low is Rs 8.70.
Q3. What is the Anlon Healthcare share price target?
Ans. Anlon Healthcare does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. Investors can check live research on the Univest Screener and consult a SEBI-registered adviser.
Q4. What does Anlon Healthcare manufacture?
Ans. Anlon Healthcare manufactures pharmaceutical intermediates and specialty chemicals, serving domestic and export pharmaceutical customers.
Q5. What is Anlon Healthcare’s market capitalisation and PE ratio?
Ans. Anlon Healthcare has a market capitalisation of approximately Rs 833 crore and trades at a price to earnings ratio of about 24.50 times, a discount to the specialty chemicals sector average PE of roughly 37.7 times.
Q6. How much did Anlon Healthcare’s profit grow in Q1 FY27?
Ans. Anlon Healthcare’s Q1 FY27 net profit grew to Rs 8.28 crore from Rs 3.55 crore a year earlier, with revenue up sharply to Rs 87.62 crore from Rs 33.31 crore.
